Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (101-110 of 279) with videos related to

Pageof 28
Sort By:
Pediatric Blood & Cancer|July 4, 2024
Non-Hodgkin lymphoma presenting with spinal cord compression: A population-based analysis of the NHL-BFM study groupAmambay Riquelme, Jana Werner, Martin Zimmermann, et al.
BMC Biotechnology|February 22, 2016
The trade-off of availability and growth inhibition through copper for the production of copper-dependent enzymes by Pichia pastorisPalanisamy Athiyaman Balakumaran, Jan Förster, Martin Zimmermann, et al.
Haematologica|August 11, 2018
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study groupNaghmeh Niktoreh, Beate Lerius, Martin Zimmermann, et al.
Blood|April 13, 2017
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trialMadita Uffmann, Mareike Rasche, Martin Zimmermann, et al.
Blood|September 28, 2011
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)Ursula Creutzig, Martin Zimmermann, Jean-Pierre Bourquin, et al.
Annals of Hematology|July 5, 2016
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemiaBirgit Burkhardt, Deniz Yavuz, Martin Zimmermann, et al.
Haematologica|July 11, 2019
<i>TP53, ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemiaStefanie V Junk, Norman Klein, Sabine Schreek, et al.
Blood|January 22, 2020
Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapyWilhelm Woessmann, Martin Zimmermann, Andrea Meinhardt, et al.
Journal of Oral Microbiology|November 12, 2024
<i>In vitro</i> plaque formation model to unravel biofilm formation dynamics on implant abutment surfacesRomualdus Nugraha Catur Utomo, Alena Lisa Palkowitz, Lin Gan, et al.
Leukemia & Lymphoma|July 4, 2018
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09Franziska Schramm, Martin Zimmermann, Norbert Jorch, et al.
Pageof 28

Showing results (101-110 of 279) with videos related to

Sort By:
Pageof 28
Pediatric Blood & Cancer|July 4, 2024
Non-Hodgkin lymphoma presenting with spinal cord compression: A population-based analysis of the NHL-BFM study groupAmambay Riquelme, Jana Werner, Martin Zimmermann, et al.
BMC Biotechnology|February 22, 2016
The trade-off of availability and growth inhibition through copper for the production of copper-dependent enzymes by Pichia pastorisPalanisamy Athiyaman Balakumaran, Jan Förster, Martin Zimmermann, et al.
Haematologica|August 11, 2018
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study groupNaghmeh Niktoreh, Beate Lerius, Martin Zimmermann, et al.
Blood|April 13, 2017
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trialMadita Uffmann, Mareike Rasche, Martin Zimmermann, et al.
Blood|September 28, 2011
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)Ursula Creutzig, Martin Zimmermann, Jean-Pierre Bourquin, et al.
Annals of Hematology|July 5, 2016
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemiaBirgit Burkhardt, Deniz Yavuz, Martin Zimmermann, et al.
Haematologica|July 11, 2019
<i>TP53, ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemiaStefanie V Junk, Norman Klein, Sabine Schreek, et al.
Blood|January 22, 2020
Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapyWilhelm Woessmann, Martin Zimmermann, Andrea Meinhardt, et al.
Journal of Oral Microbiology|November 12, 2024
<i>In vitro</i> plaque formation model to unravel biofilm formation dynamics on implant abutment surfacesRomualdus Nugraha Catur Utomo, Alena Lisa Palkowitz, Lin Gan, et al.
Leukemia & Lymphoma|July 4, 2018
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09Franziska Schramm, Martin Zimmermann, Norbert Jorch, et al.
Pageof 28